Pre-market 24 Feb 2026: IDIA.SW Idorsia Ltd (SIX) earnings due Feb 26, watch CHF3.87 catalyst
We start pre-market with the key fact: IDIA.SW stock trades at CHF 3.87 ahead of Idorsia Ltd’s earnings due 26 Feb 2026. Traders will watch revenue cadence, R&D spend, and clinical updates that could move the Swiss-listed Biotech on the SIX. The stock shows volume 911,500.00 today versus an average of 1,458,928.00 shares. We outline valuation, technicals, and Meyka AI forecasts to set expectations for the report.
Earnings trigger: IDIA.SW stock and the Feb 26 report
Idorsia reports results after market on 26 Feb 2026, creating a clear pre-market earnings trigger for IDIA.SW stock. Investors should expect commentary on daridorexant sales and pipeline progress for CNS and cardiovascular assets.
We expect the company to update guidance or trial readouts that could affect near-term revenue. The earnings announcement time is 16:30:00 UTC and could affect SIX trading the next session.
Price action and volume: IDIA.SW stock technical snapshot
IDIA.SW stock is at CHF 3.87, with a day low of CHF 3.78 and day high of CHF 4.01. Average price over 50 days is CHF 3.88 and 200-day average is CHF 3.19.
Volume today is 911,500.00 versus avg volume 1,458,928.00, giving relative volume 0.36. Momentum indicators show RSI 45.54 and MACD near neutral, indicating limited trend strength before earnings.
Fundamentals and valuation: IDIA.SW stock financials
Idorsia carries market cap CHF 729,465,865.00 and EPS of -0.62. Price is trading at PE of -5.90 on the quote feed, reflecting negative earnings.
Key ratios show price-to-sales 3.14 and EV-to-sales 8.30. Cash per share is 0.33 and current ratio is 1.40, which highlights near-term liquidity but continued negative free cash flow.
Pipeline and corporate drivers: IDIA.SW stock catalysts
Idorsia’s pipeline and partner deals are the primary fundamental drivers for IDIA.SW stock. Collaborations include Janssen on aprocitentan and licensing with Mochida for daridorexant.
Clinical milestones and commercialization updates will shape revenue and investor sentiment. We link company materials for reference: Idorsia investor relations.
Meyka AI grade and forecast: IDIA.SW stock rating and targets
Meyka AI rates IDIA.SW with a score out of 100: 72.56 / 100, Grade B+, suggestion BUY. This grade factors S&P 500 and sector comparisons, growth metrics, forecasts, and analyst signals.
Meyka AI’s forecast model projects monthly CHF 4.05, quarterly CHF 5.39, and 12-month CHF 5.43. Versus the current price CHF 3.87, that implies upside of 4.65%, 39.28%, and 40.24% respectively. Forecasts are model-based projections and not guarantees.
Earnings risks and outlook: IDIA.SW stock what to watch
Key risks for IDIA.SW stock include continued negative earnings, R&D expense volatility, and inventory cycles. Recent metrics show operating cash flow per share -0.60 and free cash flow per share -0.65.
We also flag sector context: Swiss Healthcare has outperformed in 3 months with +8.20%. That sector tailwind can help sentiment, but clinical or commercial setbacks can quickly reverse gains.
Final Thoughts
IDIA.SW stock heads into earnings on 26 Feb 2026 at CHF 3.87 with clear upside in model forecasts. We note the balanced picture: positive pipeline catalysts and partnerships versus negative EPS and ongoing cash burn. Meyka AI rates IDIA.SW 72.56/100 (B+, BUY) and models a 12-month target of CHF 5.43, implying 40.24% upside from the current price. Short-term traders should watch guidance and trial commentary at the release. Longer-term investors must weigh clinical risk against possible commercial growth in CNS products. Remember, forecasts are model outputs and not guarantees, and our grade is informational. For company filings see Idorsia investor relations and for market details visit SIX exchange. Use Meyka AI as an AI-powered market analysis platform to track real-time updates before and after the report.
FAQs
When does Idorsia report earnings and why does it matter for IDIA.SW stock?
Idorsia reports after market on 26 Feb 2026. The release may update revenue, R&D spend, and trial progress. Those items tend to move IDIA.SW stock on the SIX the following session.
What is Meyka AI’s price forecast for IDIA.SW stock?
Meyka AI’s model projects a 12-month price of CHF 5.43, implying 40.24% upside from CHF 3.87. Forecasts are projections and not guarantees.
What key financials should investors watch in the IDIA.SW earnings report?
Watch revenue trends, R&D expenses, cash flow, and guidance. IDIA.SW currently shows EPS -0.62, operating cash flow per share -0.60, and cash per share 0.33.
How does sector data affect IDIA.SW stock outlook?
Swiss Healthcare has a 3-month gain of +8.20%. Sector strength can support IDIA.SW stock, but clinical misses or weak sales can offset that help quickly.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.